BBOT

BridgeBio Oncology Therapeutics, Inc. is a leading clinical-stage biopharmaceutical firm based in South San Francisco, California, dedicated to developing targeted small molecule inhibitors for various cancer types. The company utilizes its advanced drug discovery platform to create precision medicine solutions aimed at addressing critical unmet medical needs in oncology. With a strong pipeline of therapeutics at different stages of development, BridgeBio is strategically focused on targeting specific genetic drivers of cancer, enhancing treatment efficacy and improving patient outcomes.